title: Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors.
abstract: Adeno-associated virus (AAV) liver-directed gene therapy seems a feasible treatment for Crigler-Najjar syndrome type I, an inherited liver disorder characterized by severe unconjugated hyperbilirubinemia. Transient immunosuppression coupled with vector administration seems needed to overcome host immune responses that prevent long-term expression in patients. The immunosuppressive mycophenolate mofetil (MMF), which inhibits de novo synthesis of purines, is a promising candidate. To investigate the potential use of MMF in patients with Crigler-Najjar syndrome, we studied its effect on single-stranded AAV (ssAAV)-mediated correction of hyperbilirubinemia in the relevant preclinical model, the Gunn rat. Although MMF was well tolerated and effective it also impaired the efficacy of ssAAV. Subsequent in vitro studies showed that this effect is not specific for UGT1A deficiency. In fact, clinical relevant concentrations of mycophenolic acid (MPA), the active compound of MMF, also impair the transduction of HEK-293T cells by ssAAV. Because this effect was reversed by guanosine addition, it seems that intracellular levels of this nucleotide become limited, suggesting that MPA impairs second-strand DNA synthesis. This is corroborated by observations that MPA did not impair transduction of 293T cells by a self-complementary AAV (scAAV) vector and that MMF did not reduce the scAAV efficacy in the Gunn rat. In conclusion, MMF impairs ssAAV-mediated liver-directed gene therapy, which is relevant for the use of this immunosuppressive agent with single-stranded vectors. Furthermore, because this effect is due to impaired second-strand synthesis, the use of MMF with scAAV seems warranted.
authors.affiliation: Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, 1105 BK Amsterdam, The Netherlands.
authors.forename: Paula S
authors.initials: PS
authors.lastname: Montenegro-Miranda
authors.forename: Lysbeth
authors.initials: L
authors.lastname: ten Bloemendaal
authors.forename: Cindy
authors.initials: C
authors.lastname: Kunne
authors.forename: Dirk R
authors.initials: DR
authors.lastname: de Waart
authors.forename: Piter J
authors.initials: PJ
authors.lastname: Bosma
mesh_terms: D000818:Animals; D001663:Bilirubin / Q000097:blood; D002460:Cell Line; D003414:Crigler-Najjar Syndrome / Q000235:genetics / Q000276:immunology / Q000628:therapy; D017931:DNA Primers / Q000235:genetics; D004261:DNA Replication / Q000187:drug effects; D000229:Dependovirus / Q000187:drug effects*; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D016014:Linear Models; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D051381:Rats; D011911:Rats, Gunn; D014161:Transduction, Genetic / Q000379:methods*
chemical_list: D017931:DNA Primers; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D001663:Bilirubin